(1S,5R)-7-oxo-2,6-diazabicyclo<3.2.0>heptane-6-sulfonic acid | 145574-59-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1S,5R)-7-oxo-2,6-diazabicyclo<3.2.0>heptane-6-sulfonic acid
• 英文别名: (1S,5R)-7-oxo-2,6-diazabicyclo[3.2.0]heptane-6-sulphonic acid；(1S,5R)-7-oxo-2,6-diaza-bicyclo[3.2.0]heptane-6-sulfonic acid；(1S,5R)-7-oxo-6-aza-2-azoniabicyclo[3.2.0]heptane-6-sulfonate
• CAS: 145574-59-0
• 化学式: C₅H₈N₂O₄S
• 分子量: 192.196
• InChiKey: REQJVNLCTXHOHL-DMTCNVIQSA-N

物化性质

• 密度：
  1.83±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -3.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  95.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (1S,5R)-7-oxo-2,6-diazabicyclo<3.2.0>heptane-6-sulfonic acid 在 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 (1S,5R)-2--7-oxo-2,6-diazabicyclo<3.2.0>heptane-6-sulfonic acid
  参考文献：
  名称：

  Structure-Based Design of β-Lactamase Inhibitors. 1. Synthesis and Evaluation of Bridged Monobactams

  摘要：

  Bridged monobactams are novel, potent, mechanism-based inhibitors of class C beta-lactamases, designed using X-ray crystal structures of the enzymes. They stabilize the acyl-enzyme intermediate by blocking access of water to the enzyme-inhibitor ester bond. Bridged monobactams are selective class C beta-lactamase inhibitors, with half-inhibition constants as low as 10 nM, and are less effective against class A and class B enzymes (half-inhibition constants > 100 mu M) because of the different hydrolysis mechanisms in these classes of beta-lactamases. The stability of the acyl-enzyme complexes formed with class C beta-lactamases (half-lives up to 2 days were observed) enabled determination of their crystal structures. The conformation of the inhibitor moiety was close to that predicted by molecular modeling, confirming a simple reaction mechanism, unlike those of known beta-lactamase inhibitors such as clavulanic acid and penam sulfones, which involve secondary rearrangements. Synergy between the bridged monobactams and beta-lactamase-labile antibiotics could be observed when such combinations were tested against strains of Enterobacteriaceae that produce large amounts of class C beta-lactamases. The minimal inhibitory concentration of the antibiotic of more than 64 mg/L could be decreased to 0.25 mg/L in a 1:4 combination with the inhibitor.

  DOI：

  10.1021/jm980023c
• 作为产物：
  描述：

  tert-butyl (1S,5R)-7-oxo-2,6-diazabicyclo<3.2.0>heptane-2-carboxylate 在 三氧化硫 N,N-二甲基甲酰胺络合物 、 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 、 二氯甲烷 为溶剂， 反应 6.5h， 以94%的产率得到(1S,5R)-7-oxo-2,6-diazabicyclo<3.2.0>heptane-6-sulfonic acid
  参考文献：
  名称：

  WO2008/39420

  摘要：

  公开号：

文献信息

• 顺式稠环的β-内酰胺化合物的合成方法
  申请人：中国科学院昆明植物研究所

  公开号：CN103554112B

  公开（公告）日：2016-04-13

  式（I）所示的一类顺式稠环的β-内酰胺化合物的合成方法，以取代或未取代的吡咯-2-甲酸，或取代或未取代的吡啶-2-甲酸，或取代或未取代的吲哚-2-甲酸为起始原料，采用Pd(II)为催化剂，AgOAc或Ag2CO3为氧化剂，通过钯催化对酰胺底物2（如Scheme4）的β位的sp3C-H键进行活化，同时发生分子内的C-N键形成，成功构建顺式稠环的β-内酰胺骨架作为关键步骤。本发明原料简单易得，价格低廉，实验操作简单，路线短，收率高，具有很高的原子经济性，废弃物少，对环境良好，底物适用范围宽，普适性好，能高效地得到手性保持的光学活性β-内酰胺类化合物。
• [EN] PROCESS FOR THE MANUFACTURE OF BRIDGED MONOBACTAM INTERMEDIATES<br/>[FR] PROCÉDÉ DE FABRICATION D'INTERMÉDIAIRES DE MONOBACTAM PONTÉ
  申请人：BASILEA PHARMACEUTICA AG

  公开号：WO2009037229A1

  公开（公告）日：2009-03-26

  A process for manufacturing a compound of Formula (I) which has cis-conformation and wherein R1 represents a 1-phenyl-C1-C4alkyl or 1-naphthyl-C1-C4alkyl group, wherein the phenyl or naphthyl moiety of R1 is unsubstituted or substituted with one or more C1-C4alkoxy groups and the carbon atoms in 2-, 3-, and/or 4-position of the alkyl part of R1 are, independently of the phenyl or naphthyl moiety of R1 and independently of one another, unsubstituted or substituted with C1-C4alkoxy and/or silyloxy or, preferably, are unsubstituted or substituted with one C1-C4alkoxy group and/or silyloxy group per carbon atom, and R2 represents a C1-C6alkyl group or an unsubstituted or substituted benzyl group, in which process a compound of Formula (II) wherein R3 represents a C1-C6alkyl group or an unsubstituted or substituted benzyl group, and R1 and R2 have the same meaning as in formula (I); is treated with a base at a temperature of 0°C or less in a liquid aprotic solvent for a time period sufficient to obtain the compound of formula (I).

  一种制造具有顺式构象的化合物的方法，其中R1代表1-苯基-C1-C4烷基或1-萘基-C1-C4烷基基团，其中R1的苯基或萘基部分未取代或取代为一个或多个C1-C4烷氧基团，且R1的烷基部分中的第2、3和/或第4位的碳原子，独立于R1的苯基或萘基部分以及彼此独立地，未取代或取代为C1-C4烷氧基和/或硅氧烷基，或者更好地，未取代或取代为每个碳原子一个C1-C4烷氧基和/或硅氧烷基的R2代表C1-C6烷基或未取代或取代的苄基基团，在该方法中，将具有式（II）的化合物在液态非质子溶剂中以0°C或更低的温度用碱处理足够的时间，以获得式（I）的化合物。
• NOVEL INHIBITORS OF BETA-LACTAMASE
  申请人：Blizzard Timothy A.

  公开号：US20100009957A1

  公开（公告）日：2010-01-14

  A class of 7-oxo-2,6-diazabicyclo-[3.2.0]-heptane-6-sulfonic acid compounds substituted at the two position of the bicyclic ring with a heterocyclylaminocarbonyl group or a carbocyclylaminocarbonyl group are β-lactamase inhibitors. The compounds and their prodrugs and pharmaceutically acceptable salts are useful in the treatment of bacterial infections in combination with β-lactam antibiotics. In particular, the compounds are suitable for use with β-lactam antibiotics (e.g., imipenem and ceftazidime) against micro-organisms resistant to β-lactam antibiotics due to the presence of the β-lactamases.

  一类7-氧代-2,6-二氮杂双环[3.2.0]庚烷-6-磺酸化合物，在双环环上的2位取代了杂环氨基甲酰基团或碳环氨基甲酰基团，是β-内酰胺酶抑制剂。这些化合物及其前药和药学上可接受的盐在联合β-内酰胺类抗生素治疗细菌感染方面非常有用。特别是，这些化合物适用于与β-内酰胺类抗生素（例如亚胺培南和头孢他啶）一起使用，对于由于β-内酰胺酶的存在而对β-内酰胺类抗生素产生耐药性的微生物非常有效。
• Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors
  申请人：Desarbre Eric

  公开号：US20100056478A1

  公开（公告）日：2010-03-04

  A pharmaceutically composition, comprising a combination of an antibiotically active compound of the formula (I): with a β-lactamase inhibitor of one of the formulae (II) to (XIII) are active against Gram-negative bacteria, in particular such bacteria which have become resistant against antibiotics such as aztreonam, carumonam and tigemonam. Optionally the compositions may comprise another β-lactamase inhibitor of one of the formulae (II) to (XIII), particularly of formula (V) or formula (VI).

  一种药物组合物，包括公式（I）的抗生素活性化合物与公式（II）至（XIII）中的β-内酰胺酶抑制剂的组合，对革兰氏阴性菌具有活性，特别是对已经对阿奇霉素、卡鲁莫南和替吉奴等抗生素产生耐药性的细菌具有活性。该组合物还可以包含公式（II）至（XIII）中的另一种β-内酰胺酶抑制剂，特别是公式（V）或公式（VI）的β-内酰胺酶抑制剂。
• Process for the manufacture of bridged monobactam intermediates
  申请人：Muller Marc

  公开号：US20110178291A1

  公开（公告）日：2011-07-21

  A process for manufacturing a compound of Formula (I) which has cis-conformation and wherein R1 represents a 1-phenyl-C 1 -C 4 alkyl or 1-naphthyl-C 1 -C 4 alkyl group, wherein the phenyl or naphthyl moiety of R1 is unsubstituted or substituted with one or more C 1 -C 4 alkoxy groups and the carbon atoms in 2-, 3-, and/or 4-position of the alkyl part of R1 are, independently of the phenyl or naphthyl moiety of R1 and independently of one another, unsubstituted or substituted with C 1 -C 4 alkoxy and/or silyloxy or, preferably, are unsubstituted or substituted with one C 1 -C 4 alkoxy group and/or silyloxy group per carbon atom, and R2 represents a C 1 -C 6 alkyl group or an unsubstituted or substituted benzyl group, in which process a compound of Formula (II) wherein R3 represents a C 1 -C 6 alkyl group or an unsubstituted or substituted benzyl group, and R1 and R2 have the same meaning as in formula (I); is treated with a base at a temperature of 0° C. or less in a liquid aprotic solvent for a time period sufficient to obtain the compound of formula (I).

  制备式(I)化合物的过程，其具有顺式构象，其中R1代表1-苯基-C1-C4烷基或1-萘基-C1-C4烷基基团，其中R1的苯基或萘基部分未取代或取代有一个或多个C1-C4烷氧基团，并且R1的烷基部分中2-，3-和/或4-位置的碳原子，独立于R1的苯基或萘基部分，以及彼此独立地，未取代或取代有C1-C4烷氧基和/或硅烷氧基，或者更好地，未取代或取代有每个碳原子一个C1-C4烷氧基和/或硅烷氧基，而R2代表C1-C6烷基或未取代或取代的苄基基团，在该过程中，式(II)化合物在无极性液体溶剂中，以0℃或更低的温度和碱处理足够时间，以获得式(I)化合物。